Efficacy of Osimertinib in Patients With Lung Cancer

Efficacy of Osimertinib in Patients With Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations

This is a descriptive observational study, in which data are collected in an epidemiological fashion and prospective. This study does not intend to intervene the current medical practice of the recruited patients.

Inclusion Criteria:

• Patients must be ≥18 years.
• Provision of fully informed consent prior to any study specific procedures.
• Advanced or metastatic lung squamous cell carcinoma confirmed by histology or cytology.
• According to the RECIST 1.1 standard, the patient must have at least one measurable lesion.

Exclusion Criteria:

• None